

February 16, 2023



# **Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award**

**Prestigious award presented by Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation**

PALO ALTO, Calif. and MIAMI, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Prof. Lawrence Steinman, Pasithea's Chairman and National Academy of Sciences Professor, will receive the 2023 Pioneer in Medicine Award at the 20th Annual Gathering for the Cure on February 17 as part of the 20th Annual World Congress of SBMT.

This prestigious award is given by the SBMT and the World Brain Mapping Foundation to physicians, engineers, and scientists who have contributed significantly to the field of brain mapping and therapeutics. Past recipients include Nobel Prize winner Dr. Eric Kandel, and Dr. Michael E. Phelps, the pioneer of PET imaging.

According to SBMT, the award recognized "the pioneering work in the field, including elucidating the molecular mimicry between EBNA-1 and GlialCAM, and its role in the pathogenesis of MS."

"It is an honor to be recognized by such a prestigious body of peers, especially in its 20th year of leadership in the field of brain mapping and therapeutics," commented Prof. Steinman. "MS is a debilitating disease that requires research into effective therapies and innovation in immunization. I dedicate my career to advancing these therapies for the thousands suffering from neurological diseases globally."

## **About PAS-002**

The Company's PAS-002 discovery program aims to develop a proprietary engineered DNA plasmid vaccine to tolerize the immune system to GlialCAM for the treatment of Multiple Sclerosis. GlialCAM, a CNS protein, found in the brain's white matter is attacked in MS. GlialCAM shares a component of its structure that mimics an identical component of Epstein-Barr virus nuclear antigen 1 (EBNA-1), which plays a critical role in triggering MS.

## **About Multiple Sclerosis**

MS is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. According to the National MS Society, there are more than 2.3

million people worldwide who have MS. While there is no way to predict with any certainty how an individual's disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing-remitting, secondary progressive and primary progressive. The most common affecting around 85 percent of everyone diagnosed with MS is relapsing-remitting MS (RRMS), which means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting).

### **About Pasithea Therapeutics**

Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders. We leverage our expertise in the fields of neuroscience, medicinal chemistry, and translational medicine to develop new molecular entities that target the pathophysiology underlying such diseases with the goal of bringing life-changing therapies to patients.

### **Forward Looking Statements**

This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

### **Pasithea Therapeutics Company Contact**

Dr. Tiago Reis Marques

Chief Executive Officer

Email: [tiago@pasithea.com](mailto:tiago@pasithea.com)



Source: Pasithea